Oric Pharmaceuticals
ORIC
129 hedge funds and large institutions have $612M invested in Oric Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 26 reducing their positions, and 20 closing their positions.
6,175% more call options, than puts
Call options by funds: $3.26M | Put options by funds: $52K
96% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 26
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8.42% more ownership
Funds ownership: 98.98% → 107.4% (+8.4%)
6% more funds holding
Funds holding: 122 → 129 (+7)
14% less capital invested
Capital invested by funds: $715M → $612M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.65M |
| 2 |
SCM
Superstring Capital Management
New York
|
+$5.79M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$3.95M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.89M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.5M |
| 2 |
Millennium Management
New York
|
-$2.44M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.34M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.67M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.22M |
ORIC Hedge Fund Activity: Q4 2024 in Review
129 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2024, worth a combined $612M — down 14% from $715M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ORIC positions and 20 closed out — a net gain of 7 holders — while 51 added to existing stakes and 26 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $6.65M. The largest seller was Fidelity Investments, cutting an estimated $17.5M.
- 129 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2024, up from 122 in Q3 2024.
- Funds reported $612M of Oric Pharmaceuticals stock for Q4 2024, down 14% quarter-over-quarter.
- 27 funds opened new Oric Pharmaceuticals positions in Q4 2024 and 20 closed out, a net change of +7 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2024 was Schonfeld Strategic Advisors, an estimated $6.65M added.
- The largest Oric Pharmaceuticals seller in Q4 2024 was Fidelity Investments, an estimated $17.5M sold.
Based on aggregated 13F filings for Q4 2024.